Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
JHEP Reports : Innovation in Hepatology|January 1, 2025
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 studyJean-Charles Nault, Nanthara Sritharan, Gontran Verset, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
The Lancet. Oncology|June 4, 2024
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 studyJean-Luc Van Laethem, Ivan Borbath, Hans Prenen, et al.
The Lancet. Oncology|July 7, 2022
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trialRobin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 16, 2017
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumoursCôme Lepage, Laetitia Dahan, Nadia Bouarioua, et al.
The Lancet. Gastroenterology & Hepatology|February 16, 2024
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 studyThomas Yau, Ahmed Kaseb, Ann-Lii Cheng, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Pageof 8